trending Market Intelligence /marketintelligence/en/news-insights/trending/SBXXOP0CElfYsPdoYFnyOg2 content esgSubNav
In This List

2A Pharma secures technology to develop vaccine treatments

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


2A Pharma secures technology to develop vaccine treatments

Swedish biotech 2A Pharma AB secured a license to use Medigene AG's AAVLP technology to develop vaccine treatments.

The preclinical stage, adeno-associated virus-like particles technology is believed to have the potential to develop vaccines for cancer and infectious diseases.

The technology is unrelated to Medigene's current immunotherapy programs and was a former research project at the company before it focused on T-cell immunotherapy.

Medigene will receive undisclosed milestone payments as well as royalties on sales of future AAVLP products as a result of the agreement.